Abiopharma

🔍 ASE Test, Inc. (Executive)

Company: Ainos, Inc. (AIMD)

Report Date: 2026-04-12

Detailed Transactions and Holdings:

• Acquired 5,994 shares of 6% Convertible Note due 2027 (previously due 2025) at $22.5 per share (Derivative)
  Date: 2026-04-12 | Code: P | equity_swap_involved: 0 | shares_owned_after: 105,868.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F1

Footnotes:

• F1: The convertible notes with respect to shares of common stock, $0.01 par value (the "Common Stock"), of Ainos, Inc., a Texas corporation (the "Issuer") reported herein are directly held by ASE Test, Inc., an indirectly wholly-owned subsidiary of ASE Technology Holding Co., Ltd. Accordingly, ASE Technology Holding Co., Ltd. is reporting indirect ownership of the securities held by ASE Test, Inc.
• F2: As previously reported, the Issuer and ASE Test, Inc. entered into a Convertible Note and Warrant Purchase Agreement, dated March 13, 2023 (the "2023 Convertible Note"), pursuant to which the Issuer issued convertible promissory notes to ASE Test, Inc. in the principal amount of $2,000,000 (the "Principal Amount") and six percent (6%) compounded interest of which was due on March 13, 2025. On March 10, 2025, the Issuer and ASE Test, Inc. entered into an amendment to the 2023 Convertible Note (the "Amended Convertible Note") to extend the maturity date to March 12, 2027 and change the conversion price from $7.50 per share to a conversion price equal to the lower of (a) $7.50 per share and (b) the higher of (x) the average closing price per share of the Issuer's common stock for the period of thirty (30) trading days prior to the day when the noteholder exercises the conversion right or (y) $4.50, subject to anti-dilutive adjustment as set forth in the Amended Convertible Note.
• F3: As a result of the five-for-one reverse stock split effected by the Issuer on June 30, 2025, the conversion price is now the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share of the Issuer's common stock for the period of thirty (30) trading days prior to the day when the noteholder exercises the conversion right or (y) $22.50, subject to anti-dilutive adjustment as set forth in the Amended Convertible Note.